Palumbo Wealth Management LLC Has $355,000 Stock Holdings in Exagen Inc. (NASDAQ:XGN)

Palumbo Wealth Management LLC grew its position in Exagen Inc. (NASDAQ:XGN) by 13.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 86,704 shares of the company’s stock after purchasing an additional 10,340 shares during the period. Palumbo Wealth Management LLC’s holdings in Exagen were worth $355,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of XGN. Creative Planning acquired a new stake in Exagen in the third quarter worth $110,000. Verus Capital Partners LLC acquired a new stake in Exagen in the third quarter worth $39,000. Finally, Stonepine Capital Management LLC raised its holdings in Exagen by 49.0% in the third quarter. Stonepine Capital Management LLC now owns 534,398 shares of the company’s stock worth $1,651,000 after purchasing an additional 175,701 shares during the period. 75.25% of the stock is currently owned by institutional investors and hedge funds.

Exagen Stock Down 0.9 %

Shares of NASDAQ:XGN opened at $4.23 on Friday. Exagen Inc. has a 12 month low of $1.30 and a 12 month high of $6.22. The company has a debt-to-equity ratio of 1.54, a quick ratio of 4.05 and a current ratio of 4.05. The company’s fifty day simple moving average is $4.33 and its 200 day simple moving average is $3.48.

Insider Buying and Selling

In other Exagen news, major shareholder Nmsic Co-Investment Fund, L.P. sold 200,000 shares of Exagen stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $3.30, for a total value of $660,000.00. Following the sale, the insider now directly owns 2,108,958 shares in the company, valued at approximately $6,959,561.40. The trade was a 8.66 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 26.10% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research firms have weighed in on XGN. Canaccord Genuity Group increased their target price on shares of Exagen from $5.00 to $7.00 and gave the stock a “buy” rating in a report on Friday, January 3rd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $8.00 target price on shares of Exagen in a report on Monday, January 13th. Finally, William Blair restated an “outperform” rating on shares of Exagen in a report on Wednesday, November 13th.

Exagen Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).